Prostate Cancer - Results from #160

PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. December 20, 2024

Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men. December 20, 2024

A pooled long-term follow-up after radiotherapy for prostate cancer with and without a rectal hydrogel spacer: impact of hydrogel on decline in sexual quality of life. December 20, 2024

Personalized Mobile App-Based Program for Preparation and Recovery After Radical Prostatectomy: Initial Evidence for Improved Outcomes From a Prospective Nonrandomized Study. December 20, 2024

Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis. December 19, 2024

Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials. December 19, 2024

Development and Validation of Prognostic Model for Metastatic Castration-Resistant Prostate Cancer Patients Treated With First-Line Abiraterone or Enzalutamide. December 19, 2024

Perioperative outcomes, environmental impact and economic implications of pelvic drain discontinuation in prostate cancer patients undergoing robot-assisted radical prostatectomy. December 19, 2024

Navigating Focal Therapy for Prostate Cancer: Contemporary Perspectives and Future Trajectories in the Canadian Context. December 19, 2024

Patient-reported functional outcomes and treatment-related regret in Hispanic and Spanish-speaking men following prostate cancer treatment. December 19, 2024

Masked Image Modeling Meets Self-Distillation: A Transformer-Based Prostate Gland Segmentation Framework for Pathology Slides. December 18, 2024

Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case-Control Analysis Within the EPIC Study. December 18, 2024

Administration and cancer-control outcomes of bone-modifying agents in real-world patients with metastatic castration-resistant prostate cancer. December 18, 2024

A Pilot Study of PSMA PET/CT and MRI Fusion for Prostate Cancer: Software to Replace PET/MRI Hardware. December 18, 2024

The Challenge of External Generalisability: Insights from the Bicentric Validation of a [68Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference. December 18, 2024

Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer. December 18, 2024

Genitourinary Cancer Care in Low- and Middle-Income Countries: Disparities in Incidence and Access to Care December 17, 2024

Patient preferences for life expectancy cutoffs for aggressive treatment in clinically localized prostate cancer. December 17, 2024

Five-year outcomes of moderately hypofractionated proton therapy incorporating elective pelvic nodal irradiation for high-risk prostate cancer. December 17, 2024

High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial. December 17, 2024

Page 9 of 1454